Ventricular Tachycardia treatment receives $40M funding from Field Medical

Ventricular Tachycardia treatment receives $40M funding from Field Medical

**Field Medical Targets Underserved Ventricular Tachycardia Market with $40 Million Funding**

Field Medical, a California-based startup, is making strides in the electrophysiology market with its innovative Pulsed Field Ablation (PFA) technology. The company's CEO and founder, Steven Mickelsen, is particularly focused on applying this technology to tackle ventricular tachycardia (VT), a condition that he considers a "true unmet need" in medicine due to a lack of effective drugs to manage the condition.

Field Medical recently closed an oversubscribed $40 million Series A funding round. This substantial investment, consisting of $20 million in new capital and the conversion of $20 million in seed round debt, will be used to accelerate the development of the FieldForce ablation system towards commercialization. The company aims to scale up for a pivotal trial in ventricular tachycardia and complete a first-in-human investigational trial for its PFA system to treat ventricular tachycardia, as well as another study in atrial fibrillation (AFib).

While companies like Boston Scientific and Medtronic have made significant strides in AFib treatment with their PFA systems, Field Medical's focus on VT sets it apart. The FieldForce ablation system is designed for transmural lesion creation, offering a novel approach to treat VT. By focusing on VT, Field Medical aims to penetrate an underpenetrated segment in electrophysiology, unlike competitors who have established a presence in AFib treatment.

The PFA technology is reshaping clinical practice in the electrophysiology market. Boston Scientific, for instance, has seen triple-digit growth in its electrophysiology business due to the Farapulse PFA system. Medtronic is also studying the use of PFA to treat ventricular tachycardia with its Affera and Sphere-9 technologies. Field Medical, with its focus on VT and broader application of PFA technology to treat a variety of arrhythmias, including AFib, is poised to offer a unique solution in this rapidly evolving field.

The article suggests that Field Medical may potentially compete with industry giants like Johnson & Johnson, Abbott, Boston Scientific, and Medtronic in the AFib market. However, with its specific focus on VT, the startup is well-positioned to make a significant impact in this underserved area of medicine. As Field Medical continues to advance its PFA technology and bring the FieldForce ablation system to market, it promises to revolutionise the treatment of ventricular tachycardia and potentially other arrhythmias.

1. Field Medical's PFA technology, a novel approach in the electrophysiology market, could challenge competitors like Johnson & Johnson and Abbott in the medical-conditions sector, particularly in the underserved ventricular tachycardia (VT) market.
2. The startup's recent $40 million Series A funding, a combination of new capital and debt conversion, will be instrumental in advancing the development of its FieldForce ablation device, with the aim to treat not only VT but also atrial fibrillation (AFib).
3. With AI and medtech converging in their devices, Field Medical's analytics will play a crucial role in ensuring the effectiveness of their health-and-wellness solutions, setting them apart from industry rivals.
4. Investors see potential in Field Medical's focusing on technology and finance, as they believe the startup's innovative devices could reshape the medical-conditions market, making it more accessible and efficient for people worldwide.
5. As news breaks of Field Medical's progress and technological advancements in treatment for medical-conditions such as VT and AFib, it's clear that the future of health-and-wellness lies not just with traditional players like Boston Scientific and Medtronic, but also with nimble startups leveraging the latest advancements in science and technology.

Read also: